

GENOMICS HEALTH FUTURES MISSION





MRFF disbursements

- Over \$2 billion available over first six years (>2016-17)
- **2016-17** \$65.9m = 8 programs
- **2017-18** \$1,651.7m = 11 new programs + 4 extensions
 - long term investments between four and five years
 - foundational programs clinical trials, fellowships
 - cluster of 'valley one' support program to prime pipeline
 - brave missions of various sizes
 - preventive and health services improvement focus
 - introduction of commissioned research
- THEMES: Patients, Researchers, Missions and Translation



Industry Growth Plan

Relevence to today's SUMMIT

- Genomics Health Futures Mission (\$500m/10years)
 - **Frontier Research** (\$240m/5 years) transformative health focussed research, two stages 'THE PITCH' EOI \$1m x1year = 20 competing for 'THE INVESTMENT' \$10-\$20m pa >5 years
 - **BioMedTech Horizons** (\$40m/4years, extension) bridge to commercialisation
 - Biomedical Translation Bridge (\$22.3m/4years) innovative early ideas
 - Targeted Translation Research Accelerator (\$125m/9years >2019-20)
 - Industry Researcher Exchange (\$32m/4years) joint appointment fellowships
 - Clinical Trials Activity (\$206m/5years, extension)
 - International Clinical Trial Collaboration (\$42m/5years)
 - Australian Medical Research Advisory Board (\$20m/4years)
 - AIHW Increased data linkage and release (\$30m/4years ongoing)
 - Clinical Trials National Front Door (preliminary work to develop concept)



Genomic Health Futures Mission (\$500m/10 years)


VISION: Australians living longer and better through access to genomic knowledge and technology



- FLAGSHIPS rare cancers, rare diseases and complex conditions
- CLINICAL TRIALS pre-clinical, functional genomics and targeted and adaptive clinical trials
- WORKFORCE AND RESEARCHERS creation of new highly skilled workforce and new career pathways
- COMMERCIALISATION pharmacological genomics and new to world industries
- ETHICS, LEGAL AND SOCIAL community dialogue that gains technology appreciation and value
- DATA AND ANALYTICS secure storage, access, analysis and sharing with benefit to patients



Groundwork on genomics ...





PRINCIPLES:

- The application of genomic knowledge is ethically, legally and socially responsible and community trust is promoted.
- Access and equity are promoted for vulnerable populations
- The application of genomic knowledge to health care is supported and informed by evidence and research.

NATIONAL POLICY COHESION

STRATEGIC PRIORITIES:

- 1. person-centred approach
- 2. workforce
- 3. financing
- 4. services
- 5. Data



EXTRAC1 Full report availabl THE FUTURE OF IN AUSTRALIA MACOLA

Precision medicine has a broad remit –

genomics and other omics, epigenetics, gene editing technologies and development of targeted therapies for an individual's disease profile

CATALYSTS:

- 1. advances in sequencing technology
- 2. new treatment, prediction and prevision means
- 3. collect and codify clinical and research data

Advances will reshape healthcare, invigorate the biotechnology sector and stimulate new fields of research



Australia 2030 Prosperity through

A plan for Australia to thrive in the global innovation race




Imperative 5 – Culture and ambition: Enhance the national culture of innovation by launching ambitious National Missions

Strategic opportunity 5.1

A Genomics and Precision Medicine National Mission will be an ideal first mission, delivering health and innovation benefits for all Australians



Government authority



Ministerial priorities:

- McKenzie's Mission \$20m large scale research pilot on reproductive carrier screening to generate evidence for system integration
- ProCan \$20m cancer proteomics
- Australian Genomics Cancer Medicine Program - \$50m (non-MRFF) to be matched by leveraged funding from participating centres, industry and philanthropy, to establish eight centres of excellence Australia-wide to deliver genomics-based clinical trials to around 5,000 Australians affected by rare, less common and early onset cancers



Mission Steering Committee

- Time limited convened for the explicit purpose of determining an operational plan for the Mission to be considered by Government at the end of the year
- This PLAN will among other things:
 - outline the vision and scope to drive patient outcomes and technology application
 - > define the rationale, objectives, operating principles and policy context
 - consider best governance solutions National Genomics Health Policy Framework
 - Provide a decision making framework and scientific peer review process for ensuring only the best research in funded – MRFF Funding Principles
 - determine the program logic to support investment decisions, program design and implementation
 - > provide a structured business case to support data and analytics capacity
 - > establish a monitoring, evaluation and risk framework
 - > provide a communication and community engagement framework
 - > determine specific strategies for addressing the social, ethical and legal issues



Welcome considerations from today ...

- What is a reasonable Mission scope genomics and/or beyond?
- What does success look like in 10 years time?
- What is achievable in 10 years with \$500 million?
- How can we 'scale up' rather than reinvent?
- How can we shift from 'cottage industry' to mainstream application?
- What does it mean for genomics to be business as usual?
- What capabilities are needed and how are they best organised?
- Are there any 'must have' features in the Mission archetecture to ensure success?
- What are the opportunities for leverage and growth?
- How can the ethical, legal and social issues be addressed?



More information: www.health.gov.au/MRFF MRFF@health.gov.au

2018-19 Budget Factsheets

Life saving and job creating medical research <u>www.health.gov.au</u>

Interested in accessing MRFF grants?
Register with **GRANTCONNECT** (<u>www.grants.gov.au</u>)
enables notification of new grants in areas of interest

Thank you